Sunshine Biopharma SBFM Estimates

NASDAQ SBFM
$1.13 -0.02 (-1.74%)
As of: Sep 9, 2026 · 1:19 PM EDT
Analyst Estimates

Sunshine Biopharma Inc. Revenue Estimates

Periods 18
Next Period Q3 26
Consensus 9.91 M

Analysts expect Sunshine Biopharma Inc. to report revenue of 9.91 M for Q3 26, against a range of 9.55 M to 10.27 M. The most recent reported quarter, Q2 26, came in at 9.30 M, a 0.1% beat against the 9.29 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 8.44 M9.59 M8.90 M9.41 M9.42 M8.60 M8.09 M9.30 M--------
High Estimate 12.77 M12.43 M-12.00 M11.62 M10.43 M9.42 M9.76 M10.27 M9.54 M10.06 M11.36 M12.57 M12.56 M10.03 M10.87 M
Low Estimate 11.67 M10.83 M-11.00 M9.89 M8.63 M7.81 M8.82 M9.55 M8.79 M8.82 M10.13 M10.29 M10.88 M8.69 M9.84 M
Consensus Estimate 12.22 M11.63 M-11.50 M10.75 M9.53 M8.62 M9.29 M9.91 M9.16 M9.44 M10.74 M11.43 M11.72 M9.36 M10.36 M
Analyst Estimates

Sunshine Biopharma Inc. Earnings Per Share (EPS) Estimates

Periods 18
Next Period Q3 26
Consensus -0.18

Analysts expect Sunshine Biopharma Inc. to report earnings per share of -0.18 for Q3 26, against a range of -0.19 to -0.17. The most recent reported quarter, Q2 26, came in at -1.15, a 8.7% beat against the -1.26 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) -9.40-10.10-4.40-3.90-1.90-3.00-2.50-1.15--------
High Estimate -4,914.090.11--0.98-1.17-2.32-2.46-1.18-0.17-0.29-0.86-0.580.790.392.162.59
Low Estimate -5,223.990.09--1.18-1.33-2.84-2.84-1.34-0.19-0.33-1.00-0.700.730.351.922.13
Consensus Estimate -5,069.040.10--1.08-1.25-2.58-2.65-1.26-0.18-0.31-0.93-0.640.760.372.042.36